EASTERN COOPERATIVE ONCOLOGY GROUP

东方肿瘤合作组

• 批准号: 8651973
• 负责人: Selina M Luger
• 金额: $ 33.32万
• 依托单位: UNIVERSITY OF PENNSYLVANIA
• 依托单位国家: 美国
• 财政年份: 1978
• 资助国家: 美国
• 起止时间: 1978-06-01 至 2014-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8651973
• 关键词: Abramson Cancer Center at the University of Pennsylvania; Applications Grants; Area; Beds; Cancer Center; Cancer Family; Clinical; Clinical Investigator; Clinical Research; Clinical Trials; Colon Carcinoma; Commit; Communities; Comprehensive Cancer Center; Conduct Clinical Trials; Data Quality; Development; Diffusion; Disorder by Site; Drug Industry; Eastern Cooperative Oncology Group; Eligibility Determination; Ensure; Environment; Equipment; Faculty; Financial Support; Floor; Funding; Grant; Hand; Hematology; Hospitals; Housing; Human Resources; Individual; Inpatients; Institutes; Institution; Intensive Care Units; Knowledge; Laboratories; Lead; Leadership; Left; Malignant Neoplasms; Malignant neoplasm of lung; Malignant neoplasm of prostate; Medical Oncology; Medicine; Modality; Modeling; Monitor; National Cancer Institute; Nurses; Operative Surgical Procedures; Outpatients; Patient Care; Patients; Pennsylvania; Physicians; Play; Presbyterian Church; Principal Investigator; Program Development; Protocols documentation; Protons; Radiation Oncology; Radiation therapy; Radiology Specialty; Radiosurgery; Relative (related person); Research; Research Institute; Research Personnel; Resource Sharing; Resources; Review Committee; Role; Site; Societies; Technology; Training; United States; United States National Institutes of Health; Universities; University Hospitals; anticancer research; cancer research center director; cancer therapy; cost; data management; drug development; falls; human subject; malignant breast neoplasm; multidisciplinary; multimodality; nondrug therapy; oncology; patient oriented; patient population; population based; programs; protocol development; proton therapy; square foot

DESCRIPTION (provided by applicant): This application is being submitted to continue the University of Pennsylvania's role as a main institution in the Eastern Cooperative Oncology Group beyond its 37 years of continuous particpation. The overarching objectives are to continue to serve as a scientific and administrative resource for the Group, to enter patients onto ECOG protocols, and to coordinate and support a large affiliate network. In the latter role, this application will support the diffusion of knowledge of clinical trials, assist in the proper conduct of clinical trials, and make these trials accessible to the broadest possible population of patients with cancer. Although the University of Pennsylvania has had an outstanding track record in all aspects of cooperative group activities, including accrual, administrative and scientific input and data quality, the specific aims of the proposal for the next six years are to: 1. continue to enhance accrual in all disease site and modalities, beyong our current particpation, particularly in breast and lung cancers. 2. increase physician, nurse, and data management participation in Group activities, including protocol development. 3. attract new affilaites through the Abramson Cancer Center network, allowing for enhanced availability for clinical trials participation in the larger community The relevance of this project to the ultimate cure of cancer is self-evident. Cooperative groups are the main force outside of the pharmaceutical industry dedicated to the definitve tesing of new treatments, studying not just new drug development but also non-drug treatment, such as radiation therapy and surgery, for which there would be nooter funding. These cooperative group activities, and the specific involvement of the University of Pennsylvania, represent the chief way in which the ultimate model of multimodal, collaborative patient care can be performed. The main ECOG grant describes in detail the very specific way in which clinical trials have led to RELEVANCE: Malignancies remain an enormous burden for individuals in the United States and for society as a whole. Without public support of clinical trials, both by financial support as well as participation in clinical trials, progress will not be made. If left in private hands, large areas of cancer treatment will go unexplored, denying patients the possibility of progress.

描述（由申请人提供）：提交本申请是为了继续宾夕法尼亚大学作为东部肿瘤协作组的主要机构的作用，超过其37年的连续参与。总体目标是继续作为本集团的科学和行政资源，将患者纳入ECOG方案，并协调和支持大型附属网络。在后一个角色中，该应用程序将支持临床试验知识的传播，协助临床试验的正确进行，并使这些试验可供最广泛的癌症患者人群使用。虽然宾夕法尼亚大学在合作小组活动的各个方面都有出色的记录，包括权责发生制、行政和科学投入以及数据质量，但该提案在未来六年的具体目标是：1.在我们目前的参与范围之外，继续增加所有疾病部位和模式的收益，特别是乳腺癌和肺癌。2.增加医生、护士和数据管理人员对小组活动的参与，包括方案制定。3.通过艾布拉姆森癌症中心网络吸引新的附属机构，允许在更大的社区中提高临床试验参与的可用性该项目与癌症最终治愈的相关性是不言而喻的。合作团体是制药业之外的主要力量，致力于新疗法的明确测试，不仅研究新药开发，还研究非药物治疗，如放射治疗和手术，这将有更多的资金。这些合作小组活动，以及宾夕法尼亚大学的具体参与，代表了多模式，协作病人护理的最终模式可以执行的主要方式。主要的ECOG补助金详细描述了临床试验导致 相关性：癌症仍然是美国个人和整个社会的巨大负担。如果没有公众对临床试验的支持，无论是财政支持还是参与临床试验，都不会取得进展。如果留给私人，癌症治疗的大部分领域将未经探索，剥夺了患者取得进展的可能性。

项目成果

Fludarabine phosphate therapy of non-Hodgkin's lymphoma.

磷酸氟达拉滨治疗非霍奇金淋巴瘤。

• 发表时间: 1990
• 期刊: Seminars in oncology
• 影响因子: 4
• 作者: Hochster,H;Cassileth,P
• 通讯作者: Cassileth,P

Phase II trial for the evaluation of trimetrexate in patients with inoperable squamous carcinoma of the esophagus.

评估曲美曲沙治疗不能手术的食管鳞状癌患者的 II 期试验。

• DOI: 10.1097/00000421-199210000-00007
• 发表时间: 1992
• 期刊: American journal of clinical oncology
• 作者: Falkson,G;Ryan,LM;Haller,DG
• 通讯作者: Haller,DG

Estrogen receptor-negative, progesterone receptor-positive breast carcinoma: poor clinical outcome.

• 发表时间: 1996-10
• 期刊: Archives of pathology & laboratory medicine
• 影响因子: 4.6
• 作者: A. Keshgegian;A. Cnaan

Induction therapy and intensive consolidation with daunorubicin, cytosine arabinoside, and 6-thioguanine in adult acute nonlymphoblastic leukemia.

使用柔红霉素、阿糖胞苷和 6-硫鸟嘌呤对成人急性非淋巴细胞白血病进行诱导治疗和强化巩固治疗。

• 发表时间: 1981
• 期刊: Cancer clinical trials
• 作者: Cassileth,PA;Kahn,SB;Silber,R;Weiler,C
• 通讯作者: Weiler,C

The role of radiotherapy in the management of operable locally advanced breast carcinoma - Results of a randomized trial by the Eastern Cooperative Oncology Group

• DOI: 10.1002/(sici)1097-0142(19970315)79:6<1138::aid-cncr12>3.3.co;2-b
• 发表时间: 1997-03-15
• 期刊: CANCER
• 影响因子: 6.2
• 作者: Olson, JE;Neuberg, D;Falkson, G
• 通讯作者: Falkson, G